In a recent Vital Health Podcast episode, Capitol Street’s Managing Director Ipsita Smolinski is featured along with host Duane Schulthess to unpack the IRA’s three drug-pricing pillars – from CPI-U–based inflationary rebates and Part D’s $2,000 out-of-pocket cap to the phased rollout of Medicare negotiations in 2026 – assess CBO forecasts against emerging industry data, and explore how nine- versus thirteen-year exclusivity incentives are redirecting venture capital.
In a recent Vital Health Podcast episode, Capitol Street’s Managing Director Ipsita Smolinski is featured along with host Duane Schulthess to unpack the IRA’s three drug-pricing pillars – from CPI-U–based inflationary rebates and Part D’s $2,000 out-of-pocket cap to the phased rollout of Medicare negotiations in 2026 – assess CBO forecasts against emerging industry data, and explore how nine- versus thirteen-year exclusivity incentives are redirecting venture capital.
